People suffering from Kidney cancer / Renal Carcinoma in India can hope for better treatment and have more chances of survival which would be evident from phase III clinical trial carried out by Regrow – The only cell Therapy Company in India, in association with Creagene, a Korean based Biotechnology company providing Dendritic Cell Technology.
In an exclusive interaction with Dr. Yong-Soo Bae , CEO of Creagene said, "Dendritic cells (DC) are antigen-presenting cells, and play a key role in keeping the homeostasis of immune systems by controlling immune-enhancement or immune tolerance. Dendritic cells are essential for anti-tumor immunity, thus keep humankind free from a cancer establishment in the body”.
Dendritic cells exist in extremely small quantities in the blood. The company has developed patented technology to generate pure and high titer of dendritic cells.
DC-based cancer vaccine induces strong anticancer immunity by its potent immune-inducing abilities. It is a new paradigm in cancer treatment which induces not only strong anti-tumor immunity but also immune memory to prevent tumor recurrence or metastasis.
Regrow is now entering into the Cell therapy for Oncology with our collaboration, where Regrow is the only cell Therapy Company in India with successful experience in the orthopedic segment with Autologous Chondrocyte Implantation (Chondron) & Autologous Bone Implantation (Ossron) procedures. Together with Regrow we intend to introduce the DC therapies in India. Regrow will be playing an important role to conduct human trials for the Kidney cancer treatment. This is a highly advanced and a major breakthrough in cancer treatment. More importantly, early trials done in the South Korea have shown very promising results. I hope that patients being treated in India will benefit greatly from this new
approach. DC therapies for Liver Cancer and Rheumatoid arthritis will also be introduced to India through Regrow which is in pipeline. I must add here that Regrow’s collaboration with Creagene will bring patients in India to receive a new paradigm in cancer treatment said Dr.Yong-Soo Bae.